Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

2Total

P 1 (1)

P 3 (1)

Unknown2

Recruiting2

Clinical Trials (4)

Showing 4 of 4 trials

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma

Showing all 4 trials